Roxane Laboratories must pay legal fees and costs for two defendants after filing a patent infringement suit that was “exceptionally meritless,” a federal judge in Newark has ruled.
Roxane was put on notice that its theory of liability “had substantial problems” when a ruling rejecting its motion for a preliminary injunction against Camber Pharmaceuticals and InvaGen Pharmaceuticals was affirmed by the U.S. Court of Appeals for the Federal Circuit, U.S. District Judge Stanley Chesler of the District of New Jersey ruled on Wednesday. But Roxane still pursued claims construction after the appeals court ruled on its claim that the defendants infringed on its right to manufacture generic calcium acetate capsules, Chesler ruled in Roxane Laboratories v. Camber Pharmaceuticals.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
